File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: DNALI1 expression and gene polymorphism are associated with disease recurrence after curative surgery in hepatocellular carcinoma

TitleDNALI1 expression and gene polymorphism are associated with disease recurrence after curative surgery in hepatocellular carcinoma
Authors
Issue Date2005
PublisherAmerican Association for Cancer Research
Citation
AACR 96th Annual Meeting, Anaheim, CA, 16–20 April 2005. In Cancer Research, 2005, v. 65 n. 9S, p. 289-290 Abstract no. 1246 How to Cite?
AbstractDynein, axonemal, light intermediate polypeptide 1 (DNALI1) expression was found to significantly associate with disease recurrence (hazard ratio 1.7, P=0.014) from our earlier genome-wide expression study by cDNA microarray approach on hepatocellular carcinoma (Mol Biol Cell 2002). To consolidate the prognostic significance of DNALI1 expression, we examined the second sample set (n=50) and employed quantitative RT-PCR as an independent research method to measure the transcript level in comparison to microarray quantitation with the aim to determine the DNALI1 level. The association of a higher DNALI1 expression level with early disease recurrence was again confirmed (P=0.045). From the sequence database, DNALI1 revealed a polymorphism at nucleotide 194 (codon 65), which either harbored the C-allele (GCA, alanine) or T-allele (GTA, valine). We then further examined the paralleled blood samples of the patients for gene polymorphism. The tumor DNALI1 transcript level was significantly higher in patients with T-allele compared to patients with C-allele (2.4 fold, P=0.029). DNALI1 reveals the potential as a useful molecular marker, as it provides prognostic information in general (two independent cohorts of patients) and the prediction is independent of the assay method (microarray or quantitative RT-PCR). Furthermore, the DNALI1 transcript level is associated with gene polymorphism. The biological contribution of DNALI1 for poor prognosis is unknown and warrants further investigation.
Persistent Identifierhttp://hdl.handle.net/10722/107595
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorCheung, STen_HK
dc.contributor.authorLeung, KLen_HK
dc.contributor.authorKwok, HHen_HK
dc.contributor.authorWong, SYen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-26T00:04:17Z-
dc.date.available2010-09-26T00:04:17Z-
dc.date.issued2005en_HK
dc.identifier.citationAACR 96th Annual Meeting, Anaheim, CA, 16–20 April 2005. In Cancer Research, 2005, v. 65 n. 9S, p. 289-290 Abstract no. 1246-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/107595-
dc.description.abstractDynein, axonemal, light intermediate polypeptide 1 (DNALI1) expression was found to significantly associate with disease recurrence (hazard ratio 1.7, P=0.014) from our earlier genome-wide expression study by cDNA microarray approach on hepatocellular carcinoma (Mol Biol Cell 2002). To consolidate the prognostic significance of DNALI1 expression, we examined the second sample set (n=50) and employed quantitative RT-PCR as an independent research method to measure the transcript level in comparison to microarray quantitation with the aim to determine the DNALI1 level. The association of a higher DNALI1 expression level with early disease recurrence was again confirmed (P=0.045). From the sequence database, DNALI1 revealed a polymorphism at nucleotide 194 (codon 65), which either harbored the C-allele (GCA, alanine) or T-allele (GTA, valine). We then further examined the paralleled blood samples of the patients for gene polymorphism. The tumor DNALI1 transcript level was significantly higher in patients with T-allele compared to patients with C-allele (2.4 fold, P=0.029). DNALI1 reveals the potential as a useful molecular marker, as it provides prognostic information in general (two independent cohorts of patients) and the prediction is independent of the assay method (microarray or quantitative RT-PCR). Furthermore, the DNALI1 transcript level is associated with gene polymorphism. The biological contribution of DNALI1 for poor prognosis is unknown and warrants further investigation.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofCancer Researchen_HK
dc.titleDNALI1 expression and gene polymorphism are associated with disease recurrence after curative surgery in hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailCheung, ST: stcheung@hkucc.hku.hken_HK
dc.identifier.emailKwok, HH: h0394381@hkusua.hku.hken_HK
dc.identifier.emailWong, SY: ashley@pathology.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityCheung, ST=rp00457en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.hkuros99699en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats